Neuroinflammation, especially activation of microglia, the key immune cells in the brain, has been proposed to contribute to the pathogenesis of ischemic stroke. However, the dynamics and the potential mediators of microglial activation following ischemic neuronal injury are not well understood. In this study, using oxygen/glucose deprivation and reoxygenation with neuronal and microglial cell cultures as an in vitro model of ischemic neuronal injury, we set out to identify neuronal factors released from injured neurons that are capable of inducing microglial activation. Conditioned media (CM) from hippocampal and cortical neurons exposed to oxygen/glucose deprivation and reoxygenation induced significant activation of microglial cells as well as primary microglia, evidenced by upregulation of inducible nitric oxide synthase, increased production of nitrite and reactive oxygen species, and increased expression of microglial markers. Mechanistically, neuronal ischemia-responsive protein 94 (Irp94) was a key contributor to microglial activation since significant increase in Irp94 was detected in the neuronal CM following ischemic insult and immunodepletion of Irp94 rendered ischemic neuronal CM ineffective in inducing microglial activation. Ischemic insultaugmented oxidative stress was a major facilitator of neuronal Irp94 release, and pharmacological inhibition of NADPH oxidase significantly reduced the ischemic injury-induced neuronal reactive oxygen species production and Irp94 release. Taken together, these results indicate that neuronal Irp94 may play a pivotal role in the propagation of ischemic neuronal damage. Continued studies may help identify Irp94 and/or related proteins as potential therapeutic targets and/or diagnostic/prognostic biomarkers for managing ischemiaassociated brain disorders. Keywords: complement 3 receptor, inducible nitric oxide synthase, microglial activation, oxidative stress, oxygen/ glucose deprivation. Ischemic stroke is one of the leading causes of death and disability. It is characterized by the blockage of blood flow to a certain brain region because of occlusion of a cerebral blood vessel which consequently leads to neuronal death. The ischemic lesion consists of an ischemic core region with minimal blood flow in which primary irreversible necrotic cell death occurs immediately after the ischemic insult and a potentially salvageable penumbral region with limited blood flow in which delayed secondary apoptotic cell death might occur. Neuronal damage occurs as a result of a series of detrimental events known as the ischemic cascade which include energy failure, disruption of ionic homeostasis, glutamate excitotoxicity, reactive oxygen species overproduction, and possibly neuroinflammation (Dirnagl et al. 1999 Abbreviations used: CM, conditioned media; IL-1b, interleukin-1beta; iNOS, inducible nitric oxide synthase; OGD/R, oxygen/glucose deprivation and reoxygenation; ROS, reactive oxygen species; TNFa, tumor necrosis factor-alpha.
Ischemic stroke is one of the leading causes of death and disability. It is characterized by the blockage of blood flow to a certain brain region because of occlusion of a cerebral blood vessel which consequently leads to neuronal death. The ischemic lesion consists of an ischemic core region with minimal blood flow in which primary irreversible necrotic cell death occurs immediately after the ischemic insult and a potentially salvageable penumbral region with limited blood flow in which delayed secondary apoptotic cell death might occur. Neuronal damage occurs as a result of a series of detrimental events known as the ischemic cascade which include energy failure, disruption of ionic homeostasis, glutamate excitotoxicity, reactive oxygen species overproduction, and possibly neuroinflammation (Dirnagl et al. 1999) . The ischemic insult-induced neuroinflammatory response is primarily mediated through microglia, the brain-resident immune cells (Amantea et al. 2009; Lakhan et al. 2009; Jin et al. 2010) . Several lines of evidence from human and experimental studies support a role for microglial activation in ischemic stroke pathogenesis. First, robust, yet latent microglial activation has been detected in ischemic brain regions in stroke patients and animal models many days after the ischemic insult (Thiel and Heiss 2011; Guly as et al. 2012) . Second, neutralization of the proinflammatory factors including tumor necrosis factor-alpha (Dawson et al. 1996; Barone et al. 1997) and IL-1b (Loddick and Rothwell 1996; Pradillo et al. 2012) , inhibition of nitrogen and oxygen free radicals generation from inducible nitric oxide synthase (iNOS) (Iadecola et al. 1997; Parmentier et al. 1999) and NADPH oxidase (Chen et al. 2009; Genovese et al. 2011) and deletion of toll-like receptors including TLR2 (Lehnardt et al. 2007 ) and TLR4 (Caso et al. 2007) , the main receptors that mediate microglial activation, and prostaglandin E2 EP1 receptor (Ahmad et al. 2006; Kawano et al. 2006 ) have all been shown to reduce ischemic brain damage. Third, inhibition of microglial activation by minocycline, a microglial activation modulator, has been shown to provide significant neuroprotection against brain ischemia in animal models (Yrj€ anheikki et al. 1999) and also improve the clinical outcome in stroke patients (Lampl et al. 2007) . However factors and pathways involved in neuronal injury-induced microglial activation remain poorly defined. Therefore, understanding the interaction between neuronal injury and microglial activation during ischemic insult would help discover novel mediators of the neuroinflammatory process. Neuronal factors released in response to the ischemic insult could induce microglial activation and establish a positive feedback loop of progressive neuronal damage and continuous neuroinflammation (Liu 2006; Block et al. 2007; Dutta et al. 2012) . Targeting these factors might be a promising therapeutic strategy in achieving a positive outcome in stroke patients. Elevated cellular expression of ischemia responsive protein (Irp94) in certain brain regions including hippocampus has been reported in animal models of brain ischemia, enabling the initial cloning of the gene for the protein (Yagita et al. 1999 (Yagita et al. , 2001 Koh et al. 2000) . We have also detected an increase in Irp94 in the secretome from neurotoxicant-injured midbrain dopamine neurons (Dutta et al. 2012) . Therefore, in this study, we used an in vitro model of ischemic cortical and hippocampal neuronal injury and microglial activation with ischemic neuronal insult induced by oxygen/glucose deprivation and reoxygenation (OGD/R) to determine the role of Irp94 in ischemic neuronal injury-induced microglial activation and underlying mechanisms of action (Fig. 1a) .
Experimental procedures
Cell culture Mouse hippocampal HT22 neuronal cells (RRID:CVCL_0321), initially isolated and characterized by Davis and Maher as a glutamate-sensitive subclone of the HT-4 cells (Morimoto and Koshland 1990; Davis and Maher 1994) were kindly provided by Dr. John Hong of NIEHS/NIH (Research Triangle Park, NC, USA). Rat cortical B35 neuronal cells (RRID:CVCL_1951) were purchased from American Type Culture Collection (Manassas, VA). Both HT22 and B35 neuronal cells were cultured in Dulbecco's Modification of Eagle's Medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum, 50 U/mL penicillin, and 50 lg/ mL streptomycin (neuronal maintenance media). HT22 and B35 cells were validated by verifying their expression of neuronal markers including microtubule-associated proteins 2 and neuronal Fig. 1 (a) Schematic diagram of the in vitro model of neuronal ischemia and microglial activation. Hippocampal and cortical neuronal cells were exposed to oxygen/glucose deprivation and reoxygenation to induce ischemic neuronal injury. The neuronal secretome (conditioned media) was collected and subjected to analyses to determine its Irp94 protein levels and also its microglial activation capacity. (b) Oxygen/glucose deprivation and reoxygenation (OGD/R) induces a time-dependent decrease in neuronal cell viability. Hippocampal HT22 and cortical B35 neuronal cells were exposed to different periods of OGD followed by 24 h R. Cell viability was determined using the MTT assay and expressed as a percentage of that of normoxic control cells. Results are mean AE SEM of three independent experiments performed in triplicate. *p < 0.05 compared to control. nuclear antigen NeuN by immunocytochemical analysis and their sensitivity to glutamate-induced cell death by the cell viability Methyl-Thiazolyl-Tetrazolium (MTT) assay described below. Mouse BV2 (RRID:CVCL_0182) and rat highly aggressively proliferative immortalized (HAPI) (RRID:CVCL_0F62) microglial cells were kindly provided by Dr. John Hong of NIEHS/NIH (Research Triangle Park) and were validated by verifying their expression of immune cell markers such as CD11b and induction of the inducible nitric oxide synthase (iNOS) by immunocytochemcial and Western blot analysis as described in our previous publications (Mao et al. 2007; Zhang et al. 2007; Dutta et al. 2012; Liu et al. 2013) . Both BV2 and HAPI microglial cells were cultured in DMEM supplemented with 5% fetal bovine serum, 50 U/mL penicillin, and 50 lg/mL streptomycin. Rat primary microglia were prepared from mixed glia cultures established from brains of 1-dayold Sprague Dawley rat pups and rat mixed neuron-glia cultures were prepared from gestation day 16 Sprague Dawley embryonic rat cortices following our previously published protocols (Liu et al. 2000a,b; Gao et al. 2002a,b; Zhang et al. 2009 Zhang et al. , 2010 . Primary culture preparation-related animal handling procedures were approved by the University of Florida Institutional Animal Care and Use Committee. All cell cultures were incubated at 37°C in a humidified atmosphere of 5% CO 2 and 95% air. All cell culture reagents were from Corning (Manassas, VA, USA) and Life Technologies (Carlsbad, CA, USA).
In vitro oxygen glucose deprivation (OGD)/reoxygenation (R) model Neurons were exposed to OGD/R to mimic cerebral ischemia/ reperfusion injury. For OGD/R experiments, HT22 and B35 neurons seeded in 24-well Corning Costar cell culture plates (2.5 9 10 5 cells/ well) and 10-cm Corning cell culture dishes (5 9 10 6 cells/dish)
were grown in neuronal maintenance media (0.5 mL/well and 7 mL/dish, respectively) to near confluence and primary mixed neuron-glia cultures were grown in primary neuron media (0.5 mL/ well) in 24-well Corning Costar cell culture plates. For OGD treatment, cells were rinsed (3X) with and maintained in glucosefree DMEM media for incubation at 37°C in a humidified STEMCELL Technologies (Vancouver, BC, Canada) Hypoxia Chamber (1% O 2 , 5% CO 2 , and 94% N 2 ) for the specified periods of time. At the end of OGD period, cells were switched back to fresh glucose-containing culture media and cultured under normoxic conditions for 24 h for the reoxygenation phase of the model. Cells in the control (normoxic) group were maintained in glucosecontaining culture media and incubated for the same time periods at the normoxic condition (5% CO 2 and 95% air).
Cell viability assay Neuronal cell viability was measured using the MTT colorimetric assay as previously described (Zhang et al. 2009; Sharma et al. 2010; Dutta et al. 2012) . Briefly, MTT reagent was added at the end of treatment to neuronal cells grown in 24-well plates at a final concentration of 0.5 mg/mL and the cells were incubated for 45 min at 37°C. The yellow tetrazolium MTT was reduced by the mitochondrial enzymes of viable (metabolically active) cells to a purple formazan which was solubilized in dimethyl sulfoxide. Then the absorbance was determined at 550 nm using a Synergy HT microplate reader (BioTek Instruments, Winooski, VT, USA). The absorbance was directly proportional to cell viability.
Western blot analysis for iNOS up-regulation in microglia Mouse BV2 and rat HAPI microglial cells were seeded in 10-cm cell culture dishes (5 9 10 6 cells/dish) and grown to near confluence. For treatment, cells were serum-starved for 1 h in serum-free DMEM media and then treated for 12 h at 37°C and 5% CO 2 with conditioned media (CM) from neurons exposed to normoxic condition or those exposed to 6 h OGD followed by 24 h of reoxygenation as described above. At the end of treatment, microglial cells were washed (3X) with phosphate-buffered saline (PBS) and lysed in a Tris-HCl buffer containing detergents, protease, and phosphatase inhibitors Dutta et al. 2012; Liu et al. 2013) . Total cell lysate was prepared by a brief sonication (3 9 5 second bursts) followed by centrifugation for 20 min at 20 000 g at 4°C as previously described Dutta et al. 2012; Liu et al. 2013) . Protein concentrations were determined using the bicinchoninic acid colorimetric assay (Pierce, Rockford, IL, USA) with bovine serum albumin (BSA) as a standard. Proteins were resolved on a Tris-glycine sodium dodecyl sulfate polyacrylamide gel and then transferred to nitrocellulose membranes. Following blocking of non-specific sites, the membranes were incubated overnight at 4°C with a mouse monoclonal anti-iNOS antibody (RRID:AB_397718, 1 : 2500, BD Biosciences, San Jose, CA, USA) diluted in PBS containing 3% BSA-0.1% Tween-20. Bound primary antibody was detected by incubation with horseradish peroxidase-conjugated anti-mouse secondary antibody (1 : 5000, Cell Signaling Technology, Danvers, MA, USA) followed by development using the SuperSignal West Dura chemiluminescent reagents (Pierce, Rockford, IL, USA). Images were captured using a ChemiDoc XRS digital imaging system (BioRad, Hercules, CA, USA) and analyzed using the Quantity One software as previously described Dutta et al. 2012) . In addition to loading equal amounts of proteins on the gels and using PonceauS staining of the nitrocellulose membrane to confirm proper transfer, the membrane, following detection of iNOS protein, was stripped and reprobed with anti-b-actin antibody as described Dutta et al. 2012) .
Nitrite assay Levels of nitric oxide (NO) in microglial culture supernatants were determined by measuring the amount of nitrite, a stable metabolite of NO, by a colorimetric assay using Griess reagent as previously described (Liu et al. 2000a,b; Zhang et al. 2010; Dutta et al. 2012) . Briefly, equal volumes of the culture supernatant and the reagent were mixed and kept at room temperature in the dark for 10 min. Then absorbance was measured at 540 nm and a sodium nitrite standard curve was used to determine the concentration of nitrite in the samples.
Reactive oxygen species (ROS) assay
Intracellular reactive oxygen species (ROS) levels in neurons and microglia were determined using the cell-permeable 2 0 , 7 0 -dichlorodihydrofluorescein diacetate (H2DCFDA) as previously described (Gao et al. 2003; Mao et al. 2007; Sharma et al. 2010; Zhang et al. 2010; Dutta et al. 2012) . Briefly, cells grown in 96-well culture plate were washed (2X) with phenol red-free Hank's balanced salt solution (HBSS, Hyclone) at the end of treatment, then H2DCF-DA was added to a concentration of 10 lM and the cells were incubated for 1 h at 37°C. The non-fluorescent H2DCF-DA diffused into the cells and was deacetylated by cellular esterases to H2DCF which was then oxidized by intracellular ROS to the fluorescent DCF. Fluorescence intensity was measured at 485/ 528 nm (excitation/emission) using a Synergy HT plate reader and expressed as relative fluorescence units.
Assessment of neuronal Irp94 protein release
Cold acetone precipitation was used to enrich proteins released into the neuronal CM collected after OGD/R or H 2 O 2 treatment as previously described (Dutta et al. 2012) . Briefly, neuronal CM (7 mL/dish) collected from HT22 and B35 cells grown in 10-cm culture dishes following treatment was mixed with six volumes of cold acetone (À20°C) and kept overnight at À20°C. The mixture was then centrifuged for 60 min at 9000 g at 4°C. The precipitated protein pellet was washed (2X) with fresh cold acetone and then resuspended in a Tris-HCl buffer containing detergents, protease, and phosphatase inhibitors Dutta et al. 2012; Liu et al. 2013) . The levels of Irp94 protein in the CM were then determined by Western blot analysis following the protocol described for iNOS except that the membranes were incubated with a rabbit polyclonal anti-Irp94 antibody (RRID:AB_2119815, 1 : 1000, Santa Cruz Biotechnology, Dallas, TX, USA) followed by an anti-rabbit horseradish peroxidaseconjugated secondary antibody (1 : 5000, Cell Signaling Technology, Danvers, MA, USA). Intracellular levels of Irp94 were detected by Western blot analysis of the total cell lysate prepared as described above from cells whose CM has been collected for assessing the levels of released Irp94.
Immunofluorescence
Microglial activation was also assessed in primary rat microglia using immunofluorescence staining for iNOS and complement 3 receptor (C3R), a microglial cell surface marker (Gao et al. 2002a,b; Dutta et al. 2012; Smith et al. 2014) . At the end of treatment, microglial cells grown in eight-well chamber slides (Nunc, Rochester, NY, USA) were washed (2X) with PBS and fixed for 20 min with 4% formaldehyde in PBS. The cells were washed again (2X) with PBS and then incubated for 60 min with blocking solution (PBS containing 0.2% Triton X-100, and 2% normal donkey serum). Then the cells were incubated overnight at 4°C with a mouse monoclonal anti-iNOS antibody (RRID:AB_397718, 1 : 200, BD Biosciences) or a mouse monoclonal anti-C3R antibody (OX-42) (RRID:AB_11213822, 1 : 250, BD Biosciences) diluted in the blocking solution. After washing (3X) with PBS, the cultures were incubated for 60 min with the fluorescent DY-647-conjugated anti-mouse secondary antibody (1 : 200 for iNOS and 1 : 500 for C3R, Jackson ImmunoResearch, West Grove, PA, USA). Afterward, the cells were washed (3X) with PBS and the nuclei were labeled using DAPI staining (Advanced Cell Diagnostics, Hayward, CA, USA). Cells were mounted using polyvinyl alcohol mounting medium. Fluorescent micrographs were captured at 109 using a Zeiss AxioImager M2 microscope (Carl Zeiss, Thornwood, NY, USA). Images were analyzed using ImageJ software (NIH).
Immunocytochemistry
Microglial activation in mixed neuron-glia cultures was determined by immunocytochemical analysis for C3R using the OX-42 antibody as previously described (Liu et al. 2000a,b; Gao et al. 2002a,b; Zhang et al. 2009 Zhang et al. , 2010 . Briefly, at the end of treatment, cultures grown in 24-well plates were fixed with 4% formaldehyde in PBS, blocked for 60 min with blocking solution (1% BSA, 0.4% Triton X-100, and 4% normal horse serum in PBS), and then incubated overnight at 4°C with the mouse monoclonal OX-42 antibody (RRID:AB_11213822, 1 : 250) diluted in the blocking solution. Bound primary antibodies were detected with horse anti-mouse biotinylated secondary antibody Conditioned media (CM) from hippocampal HT22 and cortical B35 neuronal cells exposed to oxygen/glucose deprivation and reoxygenation (OGD/R) were used to treat BV2 and highly aggressively proliferative immortalized (HAPI) microglia, respectively. iNOS expression was determined by immunoblotting and b-actin was used as a loading control. iNOS band intensities were normalized against that of b-actin and were expressed as mean AE SEM of three independent experiments with representative blots shown in panel (a). Nitrite levels (b) and ROS production © were also determined. ROS levels are expressed as relative fluorescence units (RFU) subtracted from that of control microglia. Results are mean AE SEM of three independent experiments. *p < 0.05 compared to control.
(1 : 250, Vector labs, Burlingame, CA, USA) followed by color development with the Vectastain ABC system (Vector Laboratories, Burlingame, CA, USA). Stained cultures were visualized using an Olympus CKX41 inverted microscope (Center Valley, PA, USA) and images were captured at 109 magnification with a Q-Imaging 3.3 MP CCD microscope camera (Surrey, BC, Canada) using the Q-Capture Suite software.
Immunodepletion
At the end of treatment, the neuronal CM (7 mL/dish) was concentrated to~250 lL using the Amicon Ultra-15 centrifugal concentrators (3 kDa cutoff; Millipore, Billerica, MA, USA). Irp94 protein was immunodepleted from the neuronal CM by immunoprecipitation using a specific anti-Irp94 antibody bound to protein A/G-coated agarose beads following a modified protocol (Dutta et al. 2012) . Briefly, neuronal CM was incubated with anti-Irp94 antibody (RRID:AB_2119815, Santa Cruz) or a polyclonal anti-glial fibrillary acidic protein antibody (RRID:AB_10013482, DAKO, Carpinteria, CA, USA), as a control, for 4 h at 4°C on a rotator. Then the protein A/G-coated agarose beads were added and rotation was continued for 2 h. After that, the mixture was centrifuged at 1000 g for 5 min and the supernatant was collected. Both the immunoprecipitate and the immunodepleted CM were immunoblotted for Irp94 to confirm its precipitation and clearance from the neuronal CM. Also, the Irp94-immunodepleted CM was used to treat microglia.
Elevation of intracellular oxidative stress in neurons
Cell permeable H 2 O 2 was used to mimic the ischemia/reperfusioninduced oxidative stress in neuronal cells. Hippocampal HT22 and Fig. 3 Ischemic cortical neuronal conditioned media induce inducible nitric oxide synthase (iNOS) and complement 3 receptor (C3R) upregulation in rat primary microglia. Primary microglia were treated with conditioned media (CM) from rat B35 neuronal cell cultures subjected to normoxic (control) and oxygen/glucose deprivation and reoxygenation (OGD/R). (a) iNOS and (b) C3R expression were determined using immunofluorescence analysis. Note that a basal level of iNOS immunoreactivity was detected in the control (top left panel) since the control microglia were treated with serum-free-based conditioned media collected from neuronal cells subjected to normoxic condition. Similar phenomenon was observed in our previous study with microglia treated with serum-free conditioned media from neurons in the control group and little iNOS expression was detected in microglia treated with regular serum-containing maintenance media in the control group, whereas robust iNOS expression was detected in microglia with a known microglia stimulus endotoxin lipopolysaccharide (LPS) (Dutta et al. 2012) . Fluorescence intensities for iNOS and C3R in nine randomly selected fields with > 10 cells per field were quantified with NIH ImageJ. Shown in panels (a) and (b) are representative micrographs for iNOS and C3R, respectively. Mean fluorescence intensities relative to that of control are expressed (bar graphs) as mean AE SEM of three independent experiments. *p < 0.05 compared to control.
cortical B35 neuronal cells grown in 24-well culture plates were treated for 24 h with 0.1-1 mM of H 2 O 2 freshly diluted in serumfree DMEM from the original 30% stock solution. For the determination of the effect of increased intracellular oxidative stress on neuronal Irp94 protein release, HT22 and B35 neuronal cells were grown in 10-cm culture dishes and treated with H 2 O 2 in serumfree DMEM before CM was collected and analyzed for Irp94 abundance as described above.
Statistical analysis and experimental design
Statistical significance was assessed using an analysis of variance (ANOVA) followed by Fisher's Least Significant Difference post hoc analysis using the JMP Pro9 software (SAS Institute, Cary, NC, USA). A p-value of < 0.05 was considered statistically significant. At the times the experiments in this study were conducted, blinding or randomization was not performed.
Results

Effect of OGD/R on neuronal cell viability
To assess their vulnerability to OGD/R, hippocampal HT22 and cortical B35 neuronal cells were exposed to different periods of OGD (0.5-24 h) followed by 24 h of reoxygenation. As shown in Fig. 1(b) , a time-dependent decrease in neuronal cell viability was observed. Susceptibility to OGD/ R-induced loss of cell viability of B35 neuronal cells was not statistically different from that of HT22 neuronal cells. Exposing cells to OGD for 6 h followed by 24 h of reoxygenation that resulted in an approximately 30% reduction in cell viability was chosen to investigate the relationship between neuronal injury and microglial activation in the subsequent studies.
Microglial activation induced by conditioned media from ischemic neurons
To determine the effect of factors released from injured neurons on microglial activity, we next treated mouse BV2 and rat HAPI microglial cells with CM from ischemic mouse hippocampal HT22 and rat cortical B35 neurons (OGD/R: 6/ 24 h), respectively, and assessed microglial activation by determining iNOS protein induction, nitrite production, and ROS generation. As shown in Fig. 2 , compared to the control, OGD/R CM caused a significant up-regulation of iNOS protein and resultant production of NO measured as nitrite as well as generation of ROS. In addition to rat HAPI microglial cells, in rat primary microglia cultures, treatment with OGD/R CM from rat B35 neuronal cells induced a significant up-regulation of iNOS protein (Fig. 3a) as well as increased immunoreactivity for complement 3 receptor, a marker for microglial activation, detected by the OX-42 antibody (Fig. 3b) . Furthermore, markedly increased OX-42 immunoreactivity as detected by immunocytochemical analysis was observed in rat primary mixed neuron-glia cultures following OGD/R treatment compared to the control cultures (Fig. 4a) . However, direct exposure of rat microglial cells to OGD/R did not Fig. 4 Oxygen/glucose deprivation and reoxygenation (OGD/R) increases microglial complement 3 receptor (C3R) expression in primary mixed neuron/glia culture. (a) Neuron/glia culture was directly exposed to OGD/R. C3R expression was determined by OX-42 immunocytochemical staining. (b) Inducible nitric oxide synthase (iNOS) expression was assessed in highly aggressively proliferative immortalized (HAPI) microglia directly exposed to OGD/R. Lipopolysaccharide (LPS) (10 ng/mL) was used as a positive control. Results shown in panels (a) and (b) are representative of two independent experiments with similar results observed in both experiments. Fig. 5 Ischemic insult promotes neuronal Irp94 release. Conditioned media (CM) and cell lysates from hippocampal HT22 and cortical B35 neuronal cells exposed to normoxic (control) oxygen/glucose deprivation and reoxygenation (OGD/R) conditions were immunoblotted for Irp94. b-actin was used as a loading control. Band intensities for released Irp94 were normalized against that of b-actin and were expressed as mean AE SEM of three independent experiments with representative blots shown in top panel. *p < 0.05 compared to control. result in iNOS induction as determined by immunoblotting for iNOS protein (Fig. 4b) , whereas a robust iNOS protein up-regulation was observed in microglia cultures treated with bacterial endotoxin lipopolysaccharide, a known stimulator of microglial activation (Gao et al. 2002a,b) . These results indicate that ischemic neuronal injury-induced microglial activation is mediated through soluble factors released from ischemic neurons.
Involvement of neuronal Irp94 in microglial activation induced by CM from ischemic neurons
We were particularly interested in exploring the role of Irp94 in the ischemic neuronal CM-induced microglial activation because of our recent report on its increased abundance in CM (> 2 fold) from neurotoxicant-injured dopamine neurons (Dutta et al. 2012 ) and its increased expression in certain brain regions in animal models of cerebral ischemia (Yagita et al. 1999 (Yagita et al. , 2001 Koh et al. 2000) . In this study, we first determined the effect of ischemic insult on the release of Irp94 from stressed neurons. As shown in Fig. 5 , levels of Irp94 in the OGD/R neuronal CM from hippocampal HT22 and cortical B35 neurons increased by 1.9 and 2.0 fold, respectively, compared to CM from normoxic neurons.
To investigate the potential contribution of neuronal Irp94 to the ischemic neuronal injury-induced microglial activation, we compared the effects of CM with and without the depletion of Irp94 on its ability to induce microglial activation. As shown in Fig. 6a , Irp94 was effectively removed from the OGD/R neuronal CM through immunoprecipitation using an anti-Irp94 antibody, while an anti-glial fibrillary acidic protein antibody (mock control) was ineffective. Next, Irp94-depleted and mock-treated OGD/R CM from hippocampal HT22 and cortical B35 neurons were compared with OGD/R and normoxic CM for their effects on microglial activation. Immunodepletion (ID) of Irp94 resulted in a significant reduction in the microglial activation capacity of the OGD/R neuronal CM from hippocampal HT22 and cortical B35 neurons as shown by the attenuated levels of iNOS protein expression and nitrite production, while mock immunodepletion had no effect ( Fig. 6b and c) . These results indicate that Irp94 plays a pivotal role in ischemic neuronal injury-induced microglial activation. and (c). Effect of Irp94 immunodepletion from OGD/R hippocampal HT22 (b) and cortical B35 (c) neuronal CM on inducible nitric oxide synthase (iNOS) expression and nitrite production in BV2 and highly aggressively proliferative immortalized (HAPI) microglia. Band intensities for iNOS were normalized against that of b-actin and were expressed as mean AE SEM of three independent experiments. Nitrite levels in the culture media (as a measure of nitrite production) in the same treatment groups with cells used for protein preparation for iNOS Western blot were measured and expressed as mean AE SEM of three experiments. *p < 0.05 compared to control and +p < 0.05 compared to OGD/R.
Effect of oxidative stress on neuronal Irp94 release Ischemia/reperfusion injury is known to induce a significant increase in reactive oxygen species, so we were interested in determining the effect of elevated oxidative stress on neuronal Irp94 release. As shown in Fig. 7(a) , when hippocampal HT22 and cortical B35 neuronal cells were treated for 24 h with 0.1-1 mM of H 2 O 2, a concentrationdependent decrease in cell viability was observed, similar to the time-dependent loss of cell viability when cells were subjected to ischemic stress (Fig. 1b) . Significant reduction in cell viability began to be observed in cells treated with 0.25 mM H 2 O 2 with a 12.6% and 16.7% reduction observed for hippocampal HT22 and cortical B35 neuronal cells, respectively (Fig. 7a) . Under this treatment condition (0.25 mM H 2 O 2 , 24 h), the amount of Irp94 in the CM from the hippocampal HT22 and cortical B35 neuronal cells increased significantly by 50 and 70% over that from control cells (Fig. 7b) . This magnitude for increased Irp94 release from H 2 O 2 -treated neurons, where a 12.6% and 16.7% reduction in viability was observed (Fig. 7a) , was smaller than the approximately twofold increase from OGD/Rstressed neurons (Fig. 5) where a 25.2À30.5% reduction in cell viability was observed (Fig. 1b) .
Next, we determined the involvement of NADPH oxidase, a major enzymatic system responsible for the generation of ROS in response to ischemia/reperfusion (Abramov et al. 2007) , in ischemic stress-induced Irp94 release. As shown in Fig. 8(a) , OGD/R caused a robust ROS generation in hippocampal HT22 and cortical B35 neurons and this OGD/R-induced ROS generation was significantly reduced by apocynin (Sigma-Aldrich) at 10 lM but not at 1 lM, while apocynin by itself at either concentrations had no significant effect on neuronal ROS generation. As an inhibitor of NADPH oxidase, apocynin works by preventing the assembly of the regulatory cytosolic subunits with the membrane-associated catalytic subunits of the multi-subunit NADPH oxidase complex (Stolk et al. 1994; Zhang et al. 2007) . Furthermore, treatment with apocynin (10 lM) significantly reduced neuronal Irp94 release induced by OGD/R (Fig. 8b) . These results suggest that NADPH oxidase-mediated ROS generation may play a role in OGD/R-induced neuronal Irp94 release.
Discussion
Irp94 is a heat-shock protein, which belongs to the HSP110 family. Expression of Irp94 has been reported to increase in response to cerebral ischemia (Yagita et al. 1999 (Yagita et al. , 2001 Koh et al. 2000) and endoplasmic reticulum stress (Kim et al. 2001 (Kim et al. , 2007 . In addition to its role as a heat-shock protein in assisting proper protein folding, Irp94 has been shown to have immunomodulatory effects through its ability to activate dendritic cells and induce iNOS up-regulation (Srivastava et al. 2008) . Moreover, the mitigated brain damage upon the deletion of its closely related family member Hsp110/105 in focal brain ischemia (Nakamura et al. 2008 ) strongly suggests that Irp94 might similarly aggravate ischemic brain damage possibly through triggering a neurotoxic inflammatory response.
In this study, using cell culture-based in vitro model, we demonstrated the interaction between ischemic neuronal injury and microglial activation in which the ischemic neuronal secretome have been shown to induce microglial activation as marked by the up-regulation of inducible nitric oxide synthase and complement 3 receptor, in addition to the increased generation of the free radicals, NO and ROS. Moreover, the increased microglial activation detected in mixed neuron/glia culture, but not in pure microglial culture, in response to ischemic insult implies that the microglial activation seen in our model was mainly because of exposure to the soluble factors released from ischemic neurons rather than direct exposure to the ischemic insult. Among these ischemic neuronal factors, Irp94 was shown to play a critical role as demonstrated by the significant increase in neuronal Irp94 release in response to ischemic insult and H 2 O 2 -induced oxidative stress where NADPH oxidase-induced oxidative stress significantly contributed to neuronal Irp94 release. More importantly, the reduced microglial activation capacity of the ischemic neuronal secretome following immunodepletion of Irp94 clearly supported a role for Irp94 in the ischemic neuronal injuryinduced microglial activation.
Inducible nitric oxide synthase (iNOS) has been used as a sensitive marker of microglial activation as it becomes readily up-regulated in response to neuronal microgliaactivating signals (Iadecola et al. 1995; Hu et al. 2012) and its inhibition has been shown to attenuate ischemic brain damage (Iadecola et al. 1997; Parmentier et al. 1999) . iNOS is mainly present in immune cells including microglia. Its importance stems from its product nitric oxide which could inflict neurotoxic effects. Nitric oxide could inhibit mitochondrial respiration and block glutamate uptake (Bal-Price and Brown 2001) which could worsen the ischemic injuryassociated energy failure and excitotoxicity, respectively. Furthermore, nitric oxide could react with superoxide free radical, which is excessively produced during ischemic injury, to form the highly reactive and neurotoxic peroxynitrite free radical (Bal-Price et al. 2002) .
Excessive ROS production is a major event in the ischemic injury cascade. ROS could wreak havoc on various cell components such as proteins, nucleic acids, and lipids causing protein misfolding, DNA damage, and lipid peroxidation which exacerbates oxidative neuronal injury. NADPH oxidase is a multi-subunit enzyme that generates the superoxide free radical through its ability to transfer an electron from NADPH to molecular oxygen. NADPH oxidase has been reported to play a crucial role in ischemic neuronal injury as evidenced by its induction in response to ischemic injury (Vallet et al. 2005 ) and the mitigated neuronal damage seen upon its inhibition (Chen et al. 2009; Genovese et al. 2011) . We showed that OGD/R induced NADPH oxidase-mediated ROS production directly in neurons and indirectly in microglia activated with the ischemic neuronal secretome. Furthermore, the increased Irp94 release seen under oxidative stress could be a mechanism through which a self-fueling loop is formed in which neuronal Irp94 released in response to oxidative stress activates microglia, which in turn produce ROS that leads to additional neuronal Irp94 release.
The validity of using oxygen/glucose deprivation with mouse hippocampal HT22 (Guo et al. 2013; Ryou et al. 2013) and rat cortical B35 (Croslan et al. 2008 ; Cao et al. 2012) neuronal cells as an in vitro model of ischemic neuronal injury has been established in several studies in which various agents were screened for their therapeutic potential. However, studies in animal models of ischemic stroke are required in order to confirm our in vitro findings and further substantiate the role of Irp94 in ischemic stroke pathogenesis.
Recent studies have revealed that microglia exhibit a wide spectrum of phenotypes, namely the various M1 and M2 phenotypes (Colonna and Butovsky 2017; Nissen 2017; Sousa et al. 2017) . Since M1 (classical) microglial activation has been implicated to contribute to ischemic neuronal injury in various experimental models as described in the Introduction section, this study focused on identification of neuronal factors that might be involved in microglial activation as judged by classical microglial activation markers such as reactive oxygen and nitrogen species (ROS and RNS). This does not exclude future studies that aim to comprehensively characterize a full spectrum of microglial activation phenotypes in response to ischemic neuronal injury.
There is an urgent need for novel therapies for ischemic stroke since few effective treatment options are currently available. Modulating the post-ischemic neuroinflammatory process is advantageous since it could attenuate the secondary neuronal damage which would in turn result in reducing the infarct size and improving the functional outcome (Amantea et al. 2009; Lakhan et al. 2009 ). Irp94-induced microglial activation in response to ischemic insult might underlie the progressive post-ischemic neuronal damage that occurs as a result of the vicious cycle of ischemic neuronal injury, release of ischemic neuronal factors (Irp94), microglial activation, aggravation of neuronal damage, and further microglial activation. Targeting ischemic neuronal factors such as Irp94 through cell-type specific gene silencing strategies or interfering with the interaction between neuronal Irp94 and its microglial effector protein (s) would interrupt this vicious cycle and halt the progression of neuronal damage. Therefore, identification of the exact molecules (i.e., receptors) on microglial cells for neuronal Irp94 protein would facilitate the process of validating neuronal Irp94 as either a potential therapeutic target for ameliorating ischemic neuronal injury and/or a diagnostic or prognostic marker for the progression of ischemic stroke in future studies in in vivo models and translational research for the ultimate application in diagnosing and managing ischemic neuronal damage in patients.
